Please use a PC Browser to access Register-Tadawul
Get It
Earnings Outlook For Travere Therapeutics
Travere Therapeutics, Inc. +0.11%
Travere Therapeutics, Inc. TVTX | 28.21 | +0.11% |
Travere Therapeutics (NASDAQ:TVTX) will release its quarterly earnings report on Thursday, 2026-02-19. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Travere Therapeutics to report an earnings per share (EPS) of $0.24.
The market awaits Travere Therapeutics's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
Historical Earnings Performance
In the previous earnings release, the company beat EPS by $0.76, leading to a 18.58% increase in the share price the following trading session.
Here's a look at Travere Therapeutics's past performance and the resulting price change:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.17 | -0.12 | -0.39 | -0.38 |
| EPS Actual | 0.59 | 0.13 | -0.19 | -0.47 |
| Price Change % | 19.00 | -2.00 | 2.00 | -7.00 |
Travere Therapeutics Share Price Analysis
Shares of Travere Therapeutics were trading at $28.75 as of February 17. Over the last 52-week period, shares are up 20.4%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.
To track all earnings releases for Travere Therapeutics visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
